Greg Jones
Senior Principal Scientist Pfizer
Seminars
Tuesday 16th September 2025
Workshop A – Debating Pan-RAS vs Pan-KRAS Inhibitors to Achieve Good Balance Between Efficacy & Toxicity for Treating Hard-to-Target Cancers
9:30 am
With the field continuing to strive to find effective, durable treatments for hard-to-target cancers such as pancreatic and colorectal cancers which contain a variety of RAS mutations. This session will engage participants in a debate and explore whether pan-RAS or pan-KRAS inhibitors offer the best balance between efficacy and toxicity, gain insights into the potential of this transformative approach for targeting multiple mutations and treating more patients.
This workshop will discuss:
- How to spare targeting of wild-type HRAS and NRAS by leveraging more specific pan-KRAS inhibitors
- How to improve therapeutic benefit by broadening the scope with pan-RAS inhibitors to treat a wider population of patients
- Are the early clinical successes of pan-RAS inhibitors more promising than initially assumed, or do pan-KRAS inhibitors still hold the edge in clinical development due to their specificity?
Wednesday 17th September 2025
A Series of Clinically Applied Small Molecule Pan-KRAS Inhibitors Arrest the KRAS GTPase Cycle to Drive Robust Anti-Tumor Efficacy in KRAS Mutant Tumor Models
9:30 am
- Pfizer’s Pan-KRASi series arrests the KRAS GTPase Cycle and blocks the interaction of KRAS with its effectors (including RAF) and interactors, including Guanine Nucleotide Exchange factor (GEFs), SOS-1
- Pfizer’s Pan-KRASi series demonstrates robust in vitro and in vivo activity across all major KRAS mutant alleles, in models representative of multiple tumor types
- Overcoming Receptor Tyrosine Kinase (RTK)-driven adaptive resistance to Pan-KRAS inhibition drives more durable ERK-MAPK pathway suppression and deeper efficacy in KRAS mutant tumor models
